From new treatment guidelines to emerging biologic therapies for psoriasis in pediatric patients, Lawrence Eichenfield, MD says there’s new hope in successfully treating this patient population. He also discusses advances in treating pediatric atopic dermatitis.
2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.
On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourth product, RHA 1, is currently in clinical trials in the US with FDA approval anticipated in 2021. Almirall seeks to enhance its early-stage research portfolio and expand its medical dermatology pipeline with three new collaborations.
New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic dermatitis.
News | October 18, 2019
New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV)...
Ortho Dermatologics Launches Telemedicine on Dermatology.com, US Cash-Pay Prescription Program
Resident of Distinction Award Celebrates 10th Anniversary at 2020 Caribbean Dermatology Symposium
DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
DermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
Post-Market Price Changes Alone Account for Most Recent Spending Growth for Biologics, and Rebates Have Little Impact